3 results
Approved WMOSuspended
Effects of NMES on physical function and skeletal muscle mass
Not approvedWill not start
Primary:• Compare progression-free survival (PFS) as assessed by the Independent Review Committee (IRC) per Response Evaluation Criteriain Solid Tumors (RECIST) Version (v) 1.1 in ociperlimab plus tislelizumab (Arm A) versus Durvalumab (Arm C) among…
Approved WMORecruiting
The aim of our study is to compare one-year outcomes in terms of major adverse cardiovascular events (all cause death, reinfarction, any revascularization and stroke) of 2 different strategies in patients with non-STEMI and multivessel coronary…